Etodolac/lidocaine

Drug Profile

Etodolac/lidocaine

Alternative Names: Etoreat; Lidocaine/etodolac; MRX-7EAT

Latest Information Update: 27 Sep 2016

Price : $50

At a glance

  • Originator MEDRx
  • Developer IL Pharma; MEDRx
  • Class Acetanilides; Analgesics; Indoleacetic acids; Local anaesthetics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute pain; Back pain

Most Recent Events

  • 01 Sep 2016 MEDRx completes a phase III trial for Acute pain in USA (NCT02695381)
  • 04 Mar 2016 MEDRx plans a phase III trial for Acute pain in USA (Topical) (NCT02695381)
  • 01 Mar 2016 MEDRx initiates enrolment in a phase III trial for Acute pain in USA (NCT02695381)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top